![]() |
市场调查报告书
商品编码
1518602
2024-2032 年按测试类型(基于 ELISA 的测试、基于 RT-PCR 的测试、登革热 IgG/IgM 快速测试等)、最终用户(医院、诊断中心等)和地区分類的登革热测试市场报告Dengue Testing Market Report by Test Type (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, and Others), End User (Hospitals, Diagnostic Centers, and Others), and Region 2024-2032 |
2023 年,IMARC Group登革热检测市场规模达到 5.842 亿美元。
登革热,也称为断骨热,是一种透过受感染的埃及斑蚊叮咬传播的病毒感染。它会导致关节和肌肉疼痛、高烧、腹痛、呕吐、呼吸困难、皮肤湿冷、头痛、眼后疼痛、疲劳、皮疹以及鼻子和牙龈轻微出血。透过登革热检测进行诊断,包括酵素连结免疫吸附测定 (ELISA)、RT-PCR 和登革热 IgG/IgM 快速检测。登革热测试由医疗专业人员使用血液样本进行,以识别登革热病毒的不同血清型。
由于全球暖化和全球蚊子繁殖地的加剧,登革热病例不断增加,这是推动市场的主要因素之一。此外,准确有效的登革热诊断在临床护理中发挥关键作用。它协助发病机制、临床试验、疫情控制、学术研究、疫苗开发、监测活动、重症病例的早期发现以及与其他传染病的病例确认和鑑别诊断。这些好处正在积极影响世界各地对登革热检测的需求。除此之外,由于生活条件差,世界各地人口稠密的地区更容易生病。再加上由于缺乏公众意识而导致的卫生和废物管理技术较差,正在刺激市场的成长。此外,医疗保健专业人员鼓励人们透过自我保护和杀虫剂热雾来预防登革热。再加上几个国家政府组织的宣传活动,正在推动市场的成长。其他促进成长的因素包括快速城市化和医疗保健行业的技术进步。此外,主要市场参与者正在广泛投资于研发(R&D)活动,以开发高效且具成本效益的登革热检测试剂盒。
The global dengue testing market size reached US$ 584.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 879.0 Million by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
Dengue, also known as breakbone fever, is a viral infection that spreads through the bite of an infected Aedes aegypti mosquito. It causes ache in the joints and muscles, high fever, abdominal pain, vomiting, difficulty in breathing, clammy and cold skin, headache, pain behind the eyes, fatigue, rashes, and mild bleeding in the nose and gums. It is diagnosed via dengue testing, which includes enzyme-linked immunosorbent assay (ELISA), RT-PCR, and dengue IgG/IgM rapid tests. Dengue testing is performed by medical professionals using a blood sample to identify the different serotypes of the dengue virus.
The growing cases of dengue on account of the rising global warming and breeding sites of mosquitos across the globe represents one of the major factors driving the market. Moreover, accurate and efficient diagnosis of dengue plays a pivotal role in clinical care. It assists in pathogenesis, clinical trials, outbreak control, academic research, vaccine development, surveillance activities, early detection of severe cases, and case confirmation and differential diagnosis with other infectious diseases. These benefits are positively influencing the demand for dengue testing around the world. Besides this, densely populated areas worldwide are more disease-prone due to low living conditions. This, along with poor sanitation and waste management techniques due to lack of public awareness, is stimulating the growth of the market. In addition, healthcare professionals are encouraging people to prevent dengue by self-protection and thermal fogging of insecticides. This, coupled with awareness campaigns organized by the government of several countries, is propelling the growth of the market. Other growth-inducing factors are rapid urbanization and technological advancements in the healthcare industry. Furthermore, key market players are extensively investing in research and development (R&D) activities to develop highly efficient and cost-effective dengue test kits.
IMARC Group provides an analysis of the key trends in each sub-segment of the global dengue testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and end user.
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
Hospitals
Diagnostic Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.